Recent Headlines
EightSpokes Announces the Launch of Their Online Presence
EightSpokes, creators of Enlighten, a SaaS-based commercial excellence platform designed with life science companies in mind, announces the launch of their online presence, EightSpokes.com. The website highlights the “Noble Eightfold Path” that inspired the company’s approach to make work more rewarding. Enlighten adopts proven social collaboration technologies and ideas from industry leaders to put teams and team members at the center of every project’s successful execution. - January 29, 2014 - EightSpokes
Dr. George Tegos Joins Advisory Board at Peptineo to Guide Antimicrobial Pipeline and Technology Development
Peptineo, a biotechnology company focused on value recovery in Pharma, announces the appointment of George Tegos, PhD, to the company's Scientific Advisory Board. "We are extremely pleased that Dr. Tegos has joined the Peptineo Scientific Advisory Board. Dr. Tegos is recognized as an emerging... - January 29, 2014 - Peptineo
Dr. Eric Bachelder Joins Advisory Board at Peptineo
Sheldon K. Jordan, PhD, President and CEO, Peptineo, announces the appointment of Eric Bachelder, PhD, to the company's Scientific Advisory Board. "We are extremely pleased that Dr. Bachelder has joined the Peptineo Scientific Advisory Board. Dr. Bachelder is recognized as an emerging... - January 18, 2014 - Peptineo
Biostratus Corporation Announces Issuance of US Patent for Tissue Bulking and Tissue Generation Technologies
Medical biotechnology company Biostratus Corporation has today announced the issuance of the USPTO Patent #8,586,089 titled "Enhanced Carriers for the Delivery of Microparticles to Mammalian Tissues and Fluids." The Biostratus patent covers a novel class of biocompatible injectable... - January 17, 2014 - Biostratus Corporation
Kimberley Beauford Joins Peptineo as Vice President of Human Capital
Industry veteran and accomplished executive, Kimberley Beauford has joined Peptineo as its new vice president of human capital. Beauford brings over 14 years of proven expertise in the delivery of innovative, strategic human capital programs to the finance and healthcare industries. Prior to... - January 14, 2014 - Peptineo
Creative Biomart Releases New Recombinant Protein Products-Human MET Mutants
Creative Biomart announces that it has launched a series of new recombinant human MET mutants. - January 11, 2014 - Creative Biomart
OsoBio Reaffirms DCAT Partnership Through New Leadership Positions
OsoBio President Milton Boyer to serve as vice president of DCAT's executive committee. - December 19, 2013 - OSO BioPharmaceuticals Manufacturing, LLC
International Polymer Solutions (IPS) Awarded ISO-9001:2008 Certification
ISO-9001:2008 Quality Certification granted to producer of plastic components for pharmaceutical, semiconductor, laboratory and other environments. International Polymer Solutions (IPS) is proud to announce their recent certification. - December 16, 2013 - International Polymer Solutions Inc.
American Regent, Inc. Takes Center Stage on The Balancing Act® Airing on Lifetime Talkshow
Make sure to tune in to The Balancing Act on December 11th and 18th at 7:00 am (ET/PT) as Blood specialist Dr. Lawrence Tim Goodnough, blood disease expert and Lynell D'Sylva, BSN, RN from American Regent explain what IDA is and introduce their innovative treatment option. - December 10, 2013 - American Regent, Inc.
Peptineo Inks Exclusive Option for Drug Delivery Technologies
Peptineo, a privately held biotechnology company, announced today that the company has inked an exclusive option for a broad set of nanotechnology patents in the area of drug delivery. Under this agreement, Peptineo will work to commercialize drug delivery technologies developed in the laboratories... - December 10, 2013 - Peptineo
Creative Biomart Introduces New Elisa Kits to Offer More Convenient and Effective Solutions
In the early November, Creative Biomart decided to introduce new Elisa Kits which include Developmental proteins ELISA kits, Granzymes and perforins ELISA kits and Growth factors/hormones ELISA kits. - November 20, 2013 - Creative Biomart
Creative Biomart Decides to Pump $300 Million to Strengthen Biosimilar Cell Lines Production
Today on the annual department meeting, Creative BioMart announces that it plans to invest more than $300 million to strengthen its biosimilar cell lines production in global range. The domain sectors of Creative BioMart are recombinant proteins, antibodies and enzymes. Several years ago, the... - November 17, 2013 - Creative Biomart
Creative Biomart Announces Commercial Agreement for Services of Biosimilar Cell Lines Manufacturing
Creative Biomart announced today that it has signed a commercial agreement for contract manufacturing pharmaceutical biosimilar cell lines for a big pharma company. - November 10, 2013 - Creative Biomart
FDAnews Announces the FDA Unique Device Identification (UDI) Rule Virtual Conference, Nov. 19
The FDA Unique Device Identification (UDI) Rule; It’s Ready for You, Are You Ready for It? FDAnews Virtual Conference; Nov. 19, 2013 — 10:00 a.m. – 4:00 p.m. EST; www.fdanews.com/UDIVirtualPR2 - November 07, 2013 - FDAnews
AnaSpec Introduces SensoLyte® 520 TEV (Tobacco Etch Virus) Protease Assay Kit
SensoLyte® 520 TEV (Tobacco Etch Virus) Protease Assay Kit is used for measuring TEV protease quantity and activity. TEV protease is widely used to remove fusion tags from recombinant proteins. - November 01, 2013 - AnaSpec, EGT Group
AveXis-BioLife Launch New Website
AveXis-BioLife is pleased to announce the launch of the company’s brand new website: www.avexisinc.com. The October 2013 unveiling of the website coincides with the company’s licensing of the gene therapy program from The Kaspar Laboratory for the treatment of Spinal Muscular Atrophy... - November 01, 2013 - AveXis Inc.
AveXis-BioLife Licenses Spinal Muscular Atrophy (SMA) Patent Portfolio from Nationwide Children's Hospital and The Ohio State University
BioLife, a synthetic biology platform company soon to be renamed AveXis, has been granted exclusive rights to the spinal muscular atrophy gene therapy program developed at The Research Institute at Nationwide Children’s Hospital and The Ohio State University in Columbus, Ohio. The license... - October 21, 2013 - AveXis Inc.
Creative Biomart Releases New Products in the Middle of Oct.
In the middle of Oct., Creative Biomart releases a new batch a products, including: Ÿ Recombinant Human MUSK, GST-tagged Ÿ Recombinant Human TIRAP, His-tagged Ÿ Native Mouse Hb Ÿ Recombinant Human NCAM2, GST-tagged Ÿ Recombinant Human NBPF15, His-tagged Ÿ Recombinant... - October 19, 2013 - Creative Biomart
AveXis BioLife Announce The Research Institute at Nationwide Children’s Hospital Received Fast Track Status for Spinal Muscular Atrophy Treatment
AveXis and BioLife, synthetic biology platform companies, today announced that The Research Institute at Nationwide Children’s Hospital received Fast Track designation from the U.S. Food and Drug Administration for its scAAV9.CB.SMN gene therapy product for the treatment of spinal muscular... - October 18, 2013 - AveXis Inc.
FDAnews Workshop: Medical Device Risk Management Conference, Nov. 5-6, Chicago, IL
Medical Device Risk Management; Beyond FMEA - New Tools to Assure Your Risk Management Program Meets New Standards *Presented by Ombu Enterprises and FDAnews* Nov. 5-6, 2013 — Chicago, IL; www.fdanews.com/MDRiskPR2 - October 04, 2013 - FDAnews
FDAnews Announces Cybersecurity Threats to Medical Devices Webinar, Oct. 18
Cybersecurity Threats to Medical Devices: Crush the Hackers Before They Crush You *FDAnews Webinar* Oct. 18, 2013 — 1:30 p.m. – 3:00 p.m. EDT www.fdanews.com/CybersecurityPR2 - September 29, 2013 - FDAnews
FDAnews Announces Pay-to-Delay Settlements in the Wake of Activis Virtual Conference
Pay-to-Delay Settlements in the Wake of Activis; Current, Former FTC Officials Offer Answers **FDAnews Virtual Conference** Oct. 15, 2013 — 10:00 a.m. – 12:30 p.m. EDT - www.fdanews.com/PayToDelayPR2 - September 25, 2013 - FDAnews
FDAnews Announces: FDA Recordkeeping, Dangerous Documents and Writing for Compliance ™
FDA Recordkeeping, Dangerous Documents and Writing for Compliance ™; Presented by FDAnews; Nov. 13-14, 2013 – Bethesda, MD; http://www.fdanews.com/DangerousDocsPR2. - September 22, 2013 - FDAnews
Creative Biomart is Going to Sign Luciferase Supply Agreement with Kasain Laboratory
After a long-term contact and discussion, Creative Biomart finally agrees to sign a Luciferase supply agreement with Kasain Laboratory, especially Native Vibrio fischeri Luciferase (http://www.creativebiomart.net/description_390631_24.htm) until Kasain finishes its study projects. The official... - September 22, 2013 - Creative Biomart
FDAnews Announces Medical Device Mobile Apps Virtual Conference – Oct. 3, 2013
Medical Device Mobile Apps; The Biosense Case: FDA Sends First Warning; FDAnews Virtual Conference; Oct. 3, 2013 — 10:00 a.m. – 4:00 p.m. EDT; www.fdanews.com/MDMobileAppsVCPR2 - September 21, 2013 - FDAnews
SignaBlok Achieves Key in Vivo Proof of Concept for Treatment of Cancer and Sepsis
Novel First-in-Class Peptide Inhibitor of TREM-1 Modulates the Inflammatory Response and Shows Promise for Treatment of Cancer and Sepsis - September 18, 2013 - SignaBlok, Inc.
International Polymer Solutions Debuts Corporate Video
Video provides overview of company products and services. - September 16, 2013 - International Polymer Solutions Inc.
Eighth Annual FDA Inspections Summit: Early Bird Registration Ends Sept. 20
Eighth Annual FDA Inspections Summit; New Powers, New Enforcement Posture, New Challenges; Presented by FDAnews; Oct. 23-25, 2013 – Bethesda, MD; www.fdanews.com/FDAInspectionsSummitPR2. - September 15, 2013 - FDAnews
AveXis Inc. Names Director, Scientific and Corporate Affairs
AveXis Inc. (avexisinc.com), a synthetic biology platform company, today announced Mindy Du as the company’s new Director of Scientific and Corporate Affairs. This is an essential position within the company, as AveXis is focused on research/development of leading-edge technology for disease... - September 13, 2013 - AveXis Inc.
International Polymer Solutions Launches New Website
TEQCOM and BECO websites merge to form new International Polymer Solutions site. - September 12, 2013 - International Polymer Solutions Inc.
Four Experts Share 80 Years of FDA Import Hold Expertise
FDA Import Holds New Powers to Control Products *FDAnews Virtual Conference Sept. 24, 2013 — 10:00 a.m. – 4:00 p.m. EDT www.fdanews.com/ImportHoldsVCPR2 - September 08, 2013 - FDAnews
Creative Biomart Launches Controlled Randomization Service for Random Nucleotide Substitutions
The GenePowerTM Controlled Randomization technology allows you to accurately direct the effective frequency of random nucleotide substitutions. And unlike error-prone PCR, you decide exactly which part(s) of the gene are affected—randomize the entire open reading frame or confine the mutagenesis to specific regions. - August 24, 2013 - Creative Biomart
AveXis Inc. Names Director of Clinical Operations and Research
AveXis Inc. (avexisinc.com), a synthetic biology platform company, today announced Minna Du as the company’s Director of Clinical Operations and Research. This is a critical position within the company, as AveXis is focused on research/development of technology for disease treatment. - August 21, 2013 - AveXis Inc.
Creative Biomart Releases New Antibody Products—Nanobodies
Creative Biomart releases new antibody products, nanobodies, recently. Compared to conventional antibodies, nanobodies also integrate the features of small molecules. - August 18, 2013 - Creative Biomart
Cheers: Researchers Identified New Brain Markers with Creative Biomart’s S100B Antibody
In the study, researchers used the critical products purchased from Creative Biomart. During the process, the serum levels of molecular markers were determined by ELISA using antibodies and antigens from Creative Biomart (New York, NY) (S100B) which you can see in the article. - August 16, 2013 - Creative Biomart
Experts from Creative Biomart Share the Experience on Using Elisa Kits to Improve the Precision of an Assay
There are some issues that researchers might meet in the process of using ELISA Kits. In order to help improve the precision of an assay, Creative Biomart (http://www.creativebiomart.net/) experts concluded the following tips for reference. - August 14, 2013 - Creative Biomart
FDAnews Webinar — Cosmetics Warning Letters Detail Rash of Problems; Webinar Provides Solutions
Is It a Cosmetic, a Drug or Both? 15-Year Regulatory Veteran Shares Compliance Secrets Presented by FDAnews Aug. 23, 2013 • 1:30 p.m. – 3:00 p.m. EDT http://www.fdanews.com/CosmeticsWebinarPR2 - August 11, 2013 - FDAnews
Research Antibody Survey: Creative Biomart Conducted a Survey Among Antibodies Users
In order to direct market and perfect products, Creative Biomart conducted the survey. And the survey results are listed as follows. - August 03, 2013 - Creative Biomart
AveXis Inc. Names Chief Scientific Officer
AveXis Inc. (avexisinc.com), a synthetic biology platform company focused on research and development of technology for disease treatment, today announced Dr. Allan A. Kaspar will serve as the company’s first Chief Scientific Officer (CSO). Dr. Kaspar has held research positions at multiple... - August 01, 2013 - AveXis Inc.
Wescadia Group’s White Paper - Pursuing Growth: Optimizing Business Development Opportunities
Wescadia Group, a healthcare consultancy firm, announces the release of its white paper entitled “Pursuing Growth: Optimizing Business Development Opportunities.” - July 31, 2013 - Wescadia Group Pty Ltd
New Company Formed to Focus on New Technology for Disease Treatment
AveXis Inc. (avexisinc.com) announced its formation as a company focused on research and development of technology specifically for disease treatment. A synthetic biology platform company, AveXis has, at its core, a desire to establish unique industry alliances which will bring innovative... - July 27, 2013 - AveXis Inc.
New Research Validates Importance of Central Lab to Overall Investigator Satisfaction
More than 250 Clinical Investigators Indicate Central Lab Preference - July 26, 2013 - Life Science Strategy Group, LLC
FDAnews Announces Leading the Climb: Seven Essentials of GMP
Leading the Climb: Seven Essentials of GMP; Presented by LearningPlus and FDAnews;Aug. 19-20, 2013 – Philadelphia, PA; www.fdanews.com/LeadingClimbPR2 - July 26, 2013 - FDAnews
OsoBio Appoints Lindsey Pruitt to Manage East Coast Business Development Efforts
Working in her new capacity in OsoBio’s Philadelphia location, Pruitt will identify and foster new business opportunities throughout the Northeast. - July 22, 2013 - OSO BioPharmaceuticals Manufacturing, LLC
Educational Seminar for Manufacturers
An educational seminar, “LEAN as a Growth Strategy,” presented by industry experts Brad Muir and Gary Conner from Technical Change Associates will be held at the Courtyard Marriott, 3020 Riffel Drive, Salina, Kansas on Thursday, August 8th at 1:00pm, registration beginning at... - July 11, 2013 - Kasa Companies
Creative Biomart Launched Novel Animal-free Recombinant Proteins for Stable Research
The novel animal-free protein production system is more efficient, fast, flexible and cheap compared to transgenic plants recombinant proteins production; the scaling-up compared with bio-reactors is simple and lineal. It doesn't have issues with inclusion bodies as E.coli. - June 28, 2013 - Creative Biomart
OsoBio Names Kathleen Larese Director of Laboratories
OsoBio has named Kathleen Larese director of laboratories. As part of OsoBio’s quality control department, the microbiology and chemistry laboratories that Larese now directs are responsible for environmental monitoring, analytical method development, and testing all incoming raw materials,... - June 26, 2013 - OSO BioPharmaceuticals Manufacturing, LLC
Creative Biomart Scientists Found That Shutdown Gene Arih2 May Treat Hepatitis
Arih2 was found within the sentinel dendritic cells of the immune system, which play a vital role in defending intruders. - May 31, 2013 - Creative Biomart
Creative BioMart Funded Research Found Another Anticancer Strategy - Targeting Cyclin D
Researchers successfully silenced abnormal proteins that control cells' growth cycle. - May 10, 2013 - Creative Biomart
OsoBio Appoints David M. Lee Vice President of Quality
OsoBio has named David M. Lee vice president of quality. Lee is responsible for overseeing all quality-related functions to ensure the company’s continued compliance with Current Good Manufacturing Practices (cGMP), including quality systems, quality control and manufacturing quality... - May 10, 2013 - OSO BioPharmaceuticals Manufacturing, LLC